TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00502190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring positioned in the vagina, around the cervix
Description: Silicon ring positioned in the vagina, around the cervix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring positioned in the vagina, around the cervix
Description: Silicon ring positioned in the vagina, around the cervix
Study: NCT02059590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridinylmethyl-14C-labeled isavuconazonium sulfate
Description: Intravenous
Study: NCT03891901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally
Study: NCT01182831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous fluoro guided celiac plexus neurolysis
Description: It is percutaneous injection of neurolytic agent in and around the celiac ganglion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided neurolysis
Description: It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
Study: NCT01069497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention of infections program
Description: The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec.
Study: NCT03400800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT01698528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet Computer
Study: NCT02868346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anal swab
Study: NCT04340973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study: NCT01470170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
Study: NCT01757548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open operation
Description: high ligation of spermatic vein by open operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgery
Description: high ligation of spermatic vein by microsurgery
Study: NCT01425112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Surgery for complications of trabeculectomy
Study: NCT03978767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: NSAID pain medication to be used in the experimental bundle for postpartum analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Analgesic medication to be used in both treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Analgesic medication to be used in both treatment arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Analgesic medication to be used in both treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Analgesic medication to be used in both treatment arms
Study: NCT01947933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab- IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study: NCT02991521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast exam
Description: Positional change before Fast exam
Study: NCT03948945

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Profile HaloTM Mixed Fractional Laser
Description: Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
Study: NCT01379144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 75 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 100 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study: NCT01373619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: ivabradine titrated to 7.5 mg BID
Study: NCT06023797

Intervention type: DRUG
Intervention: Neoadjuvant immunochemotherapy
Description: Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
Study: NCT03040531

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Description: 27mg bid in tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Oral Tablet
Description: 70 mg/week in tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + vitamin D3 tablet
Description: 500mg Calcium + 200 IU Vitamin D3 bid in tablets
Study: NCT02096913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolormin® extra (Ibuprofen)
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolormin® extra (Ibuprofen)
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment.
Study: NCT00564239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: 12 children group sessions, 8 parent group sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: 12 children group sessions
Study: NCT02741778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive group
Description: In this group, all manipulations are finished by laparoscopy and thoracoscopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open group
Description: Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
Study: NCT01498549

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine 40mg and 80mg compared to the sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill compared to Atomoxetine 40mg and 80mg.
Study: NCT03188198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
Study: NCT02238366

Intervention type: DRUG
Intervention: triptorelin
Description: This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
Study: NCT01243281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFN and entecavir
Description: The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
Study: NCT03641157

Intervention type: OTHER
Intervention: Easy Intubation

Intervention type: OTHER
Intervention: Easy Intubation
Study: NCT00944554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline given twice a day or five weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given twice a day or five weeks.
Study: NCT00894192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Izon Wavefront-guided lenses
Description: Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional lenses
Description: We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
Study: NCT03452787

Intervention type: OTHER
Intervention: None, cohort studies
Description: this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.

Intervention type: OTHER
Intervention: None, cohort studies
Description: this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.

Intervention type: OTHER
Intervention: None, cohort studies
Description: this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
Study: NCT01939457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study: NCT00080626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg injection on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg per meter-squared, every 14 days for 4 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: lumpectomy or mastectomy at end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: treatment prior to definitive breast surgery
Study: NCT00658528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
Study: NCT03834090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rESWT
Description: rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercises
Description: A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
Study: NCT03665545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMA950/Poly-ICLC
Description: IMA950 mixed with Poly-ICLC administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA950/Poly-ICLC
Description: IMA950 mixed with Poly-ICLC administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA950/Poly-ICLC and pembrolizumab
Description: IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
Study: NCT02479282

Intervention type: PROCEDURE
Group type: OTHER
Intervention: natural cesarean section

Intervention type: PROCEDURE
Group type: OTHER
Intervention: traditional cesarean section
Study: NCT03290768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Study: NCT03153657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam-Beta-Cyclodextrin
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Piroxicam-Beta-Cyclodextrin
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
Study: NCT02332759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Materna Medical
Study: NCT03491410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Low Dose
Description: Low-Dose Aspirin is to be added in the standard patient´s treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is to be added in the standard patient´s treatment
Study: NCT04002544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTG patch
Description: A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gauze cover
Description: A gauze will be applied near the radial artery pulsation to ensure blinding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gauze cover
Description: A gauze will be applied near the radial artery pulsation to ensure blinding
Study: NCT02989935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation
Description: Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal EMG
Description: Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phrenic magnetic stimulation
Description: Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
Study: NCT02810028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
Study: NCT03695068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Intervention
Description: Described in Arms description.
Study: NCT02677155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 8 Gy single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intranodal injection 5 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells
Description: Intranodal injection of 1 x 10 e8 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subcutaneous injection of 50 ug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion of 200 mg
Study: NCT01227551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A21 (CVA21)
Description: CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
Study: NCT00931489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab (Lucentis(R))
Description: 0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab (Lucentis(R))
Description: 0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab (Lucentis(R))
Description: 0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
Study: NCT03463590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral surgical implantation of DBS system to habenula
Description: The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.